We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+5.26%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$57.2B
AUM Growth
+$551M
(+0.97%)
Cap. Flow
-$331M
Cap. Flow
% of AUM
-0.58%
Top 10 Holdings %
Top 10 Hldgs %
31.76%
Holding
1,006
New
143
Increased
295
Reduced
385
Closed
137
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$247M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$183M |
| 3 |
WCC
WESCO International
WCC
|
+$178M |
| 4 |
Gilead Sciences
GILD
|
+$154M |
| 5 |
Delta Air Lines
DAL
|
+$145M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRO
Marathon Oil Corporation
MRO
|
+$221M |
| 2 |
3M
MMM
|
+$157M |
| 3 |
MRSH
Marsh
MRSH
|
+$120M |
| 4 |
Johnson & Johnson
JNJ
|
+$106M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.09% |
| 2 | Healthcare | 13.87% |
| 3 | Financials | 11.48% |
| 4 | Consumer Discretionary | 10.65% |
| 5 | Industrials | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
CG Oncology
CGON
$6.39B
| $5.74M | 0.01% |
200,000
-200,000
| -50% | -$6.84M |
|
702
Shattuck Labs
STTK
$704M
| $5.66M | 0.01% |
4,675,000
+1,775,000
| +61% | +$2.2M |
|
703
Fox Class B
FOX
$21.9B
| $5.64M | 0.01% |
123,265
-1,100
| -0.9% | -$46.3K |
|
704
Cardiff Oncology
CRDF
$74.3M
| $5.61M | 0.01% |
+1,292,308
| New | +$4.04M |
|
|
SILA
705
DELISTED
Sila Realty Trust
SILA
| $5.59M | 0.01% |
230,000
+115,969
| +102% | +$2.92M |
|
706
C4 Therapeutics
CCCC
$400M
| $5.58M | 0.01% |
1,550,000
+1,030,000
| +198% | +$5.12M |
|
707
Erie Indemnity
ERIE
$13.1B
| $5.48M | 0.01% |
13,300
-10,200
| -43% | -$4.57M |
|
708
Five Star Bancorp
FSBC
$1.13B
| $5.48M | 0.01% |
182,059
+12,214
| +7% | +$383K |
|
709
HBT Financial
HBT
$1.31B
| $5.42M | 0.01% |
247,692
-17,604
| -7% | -$401K |
|
710
Arbutus Biopharma
ABUS
$913M
| $5.4M | 0.01% |
1,650,941
-1,250,000
| -43% | -$4.6M |
|
711
Immunome
IMNM
$2.89B
| $5.31M | 0.01% |
500,000
+280,000
| +127% | +$3.38M |
|
712
California Resources
CRC
$4.56B
| $5.19M | 0.01% |
100,000
-50,000
| -33% | -$2.72M |
|
713
Fox Class A
FOXA
$24.6B
| $5.18M | 0.01% |
106,619
-105,100
| -50% | -$4.73M |
|
714
Albemarle
ALB
$14B
| $5.15M | 0.01% |
59,779
-83,000
| -58% | -$8.27M |
|
715
Ralph Lauren
RL
$22.7B
| $5.11M | 0.01% |
+22,126
| New | +$4.72M |
|
716
Axsome Therapeutics
AXSM
$11B
| $5.08M | 0.01% |
60,000
-465,000
| -89% | -$42.8M |
|
|
RVNC
717
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.03M | 0.01% |
1,653,689
+603,689
| +57% | +$2.63M |
|
718
Dick's Sporting Goods
DKS
$17.9B
| $4.92M | 0.01% |
+21,500
| New | +$4.51M |
|
719
Stock Yards Bancorp
SYBT
$2.63B
| $4.89M | 0.01% |
+68,300
| New | +$4.81M |
|
720
Algoma Steel
ASTL
$471M
| $4.89M | 0.01% |
500,000
+200,000
| +67% | +$2.06M |
|
|
CNR
721
Core Natural Resources Inc
CNR
$4.22B
| $4.8M | 0.01% |
45,000
+13,000
| +41% | +$1.5M |
|
|
DRUG
722
Bright Minds Biosciences
DRUG
$785M
| $4.77M | 0.01% |
+132,500
| New | +$4.66M |
|
723
Lifezone Metals
LZM
$355M
| $4.69M | 0.01% |
674,854
| – | – |
|
724
PENN Entertainment
PENN
$2.63B
| $4.6M | 0.01% |
+232,253
| New | +$4.56M |
|
725
Carlyle Group
CG
$17.9B
| $4.52M | 0.01% |
+89,600
| New | +$4.54M |
|
Similar funds
Adage Capital Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Adage Capital Partners held 1,006 positions worth $57.2B, up 0.97% from $56.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Adage Capital Partners's Q4 2024 filing shows 143 new, 295 increased, 385 reduced and 137 closed positions. Its largest new stake was Gilead Sciences: 1,714,130 shares worth $158M. The largest sale was Marathon Oil Corporation, an estimated $221M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q4 2024 buy was Gilead Sciences: 1,714,130 shares worth $158M.
- Adage Capital Partners added most to ConocoPhillips in Q4 2024, an estimated $247M increase.
- Adage Capital Partners's biggest Q4 2024 reduction was 3M, cutting an estimated $157M.
- Adage Capital Partners fully exited Marathon Oil Corporation in Q4 2024, selling an estimated $221M.
- Adage Capital Partners's ten largest holdings make up 32% of its $57.2B portfolio in Q4 2024.
- Adage Capital Partners opened 143 new positions and closed 137 in Q4 2024.
- Adage Capital Partners's portfolio value rose 0.97% quarter-over-quarter to $57.2B.
Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.